BERLIN--(Marketwire - Aug 17, 2012) -
MagForce AG /
MagForce AG: Dr. Jan zur Hausen elected to the Supervisory Board of
MagForce AG
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
* Renowned life sciences and investment banking expert strengthens the
company's Supervisory Board
MagForce AG (Frankfurt, XETRA: MF6), a
leading medical device company in the field of nanomedicine with
focus on
oncology, announced today that Dr. Jan zur Hausen was unanimously elected
to the
company's Supervisory Board at yesterday's Annual General Meeting. He is
taking
over from Dr. Stefan Elßer, who resigned effective as of the end of
the Annual
General Meeting.
Dr. Jan zur Hausen (born in 1965) is a managing shareholder of
Bergmann zur
Hausen & Cie. GmbH, a corporate finance company that evolved from
Sal.
Oppenheim's investment banking activities. While at Sal. Oppenheim,
Dr. zur
Hausen was responsible for numerous transactions in the life sciences
area as
Senior Vice President and Head of Healthcare.
Dr. zur Hausen has in-depth knowledge of health sciences and investment
banking.
He has a degree in biology, gained a Ph.D. in cell biology from the
University
of Basel, and previously worked at Hoffmann-La Roche, MPM Capital,
Mulligan
BioCapital, and DVC Deutsche Venture Capital, among others.
Dr. zur Hausen has known MagForce for many years now. "Dr. zur Hausen
is an
excellent addition to the Supervisory Board thanks to his many years'
experience
in the areas of both life sciences and investment banking. We see his
election
as offering strong support for our current corporate strategy,"
commented Dr.
Andreas Jordan, Executive Board of MagForce AG. "We are convinced
that his
expertise will enable him to provide us with important advice as we
continue on
our path and we would like to thank Dr. Elßer, who worked
dedicatedly for
MagForce for many years, for resigning from the Supervisory Board and
making
this step possible."
"I am looking forward to the challenges at MagForce AG and to my new
tasks,"
said Dr. Jan zur Hausen following his election. "MagForce is going
through a
difficult period at the moment, but it is on the right track. I hope that I
will
be able to make a positive contribution to the company's future
development."
About MagForce AG
MagForce AG is a leading medical technology company in the field of
nanomedicine
in oncology. The Company's proprietary NanoTherm® therapy enables
the targeted
treatment of solid tumors through the intratumoral generation of
heat via
activation of magnetic nanoparticles. NanoTherm®,
NanoPlan®, and
NanoActivator™ are components of the therapy and have received
EU-wide
regulatory approval as medical devices for the treatment of brain
tumors.
MagForce, NanoTherm, NanoPlan, and NanoActivator are trademarks of
MagForce AG
in selected countries. For more information, please visit www.magforce.com.
Disclaimer
This release may contain forward-looking statements and information that
may be
identified by formulations using terms such as "expects", "aims",
"anticipates",
"intends", "plans", "believes", "seeks", "estimates", or "will". Such
forward-looking statements are based on our current expectations
and certain
assumptions, which may be subject to a variety of risks and
uncertainties. The
results actually achieved by MagForce AG may differ substantially from
these
forward-looking statements. MagForce AG assumes no obligation to update
these
forward-looking statements or to correct them in case of developments
differing
from those anticipated.
MagForce_Press Release_Jan zur Hausen_Aug 17, 2012:
http://hugin.info/143761/R/1634696/524958.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MagForce AG via Thomson Reuters ONE
[HUG#1634696]